Herceptin: From the Bench to the Clinic

REFERENCES

• Borg A., Baldetor B., Ferno M., et al. erbB-2 Amplification in Breast Cancer with a High Rate of Proliferation. Oncogene 1991; 6: 137–143
   PubMed Web of Science ®Google Scholar
• Nicholson S., Wright C., Sainsbury R. C., et al. Epidermal Growth Factor Rceptor (EGFr) as a Marker for Poor Prognosis in Node-Negative Breast Cancer Patients: Neu and Tamoxifen Failure. J. Steroid. Biochem. Molec. Biol. 1990; 37: 811–814
   PubMed Web of Science ®Google Scholar
• Slamon D. J., Clark G. M., Wong S. G., et al. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene. Science 1987; 235: 177–182
   PubMed Web of Science ®Google Scholar
• Hynes N. E., Stern D. F. The Biology of erbB-2/ neu/HER-2 and Its Role in Cancer. Biochem. Biophys. Acta. 1994; 1198: 165–184
   PubMed Web of Science ®Google Scholar
• De Placido S., Carlomagno C., De Laurentiis M., Bianco A. R. c-erbB2 Expression Predicts Tamoxifen Efficacy in Breast Cancer Patients. Breast Cancer Res. Treat. 1998; 52: 55–64
   PubMed Web of Science ®Google Scholar
• Pegram M. D., Pauletti G., Slamon D. J. HER-2/neu as a Predictive Marker of Response to Breast Cancer Therapy. Breast Cancer Res. Treat. 1998; 52: 65–77
   PubMed Web of Science ®Google Scholar
• Colomer R., Montero S., Lluch A., Ojeda B., Barnadas A., Casado A., Massuti B., Lloveras B. Circulating erbB-2 and Resistance to Chemotherapy in Advanced Breast Cancer, (submitted)
   Google Scholar
• Hudziak R. M., Lewis G. D., Winget M., et al. p185HER2 Monoclonal Antibody Has Antiproliferative Effects in Vitro and Sensitizes Human Breast Tumors to Tumor Necrosis Factor. Mol. Cell. Biol. 1989; 9: 1165–1172
   PubMed Web of Science ®Google Scholar
• Fendly B. M., Winget M., Hudziak R. M., et al. Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product. Cancer Res. 1990; 50: 1550–1558
   PubMed Web of Science ®Google Scholar
• Kern J. A., Torney L., Weiner D., et al. Inhibition of Human Lung Cancer Cell Line Growth by an Anti-p185HER2 Antibody. Am. J. Respir. Cell. Mol. Biol. 1993; 9: 448–454
   PubMed Web of Science ®Google Scholar
• Benz C. C., Scott G. K., Sarup J. C., et al. Estrogen-dependent, Tamoxifen-resistant Tumorigenic Growth of MCF-7 Cells Transfected with HER2/neu. Breast Cancer Res. Treat. 1993; 24: 85–95
   Web of Science ®Google Scholar
• Scott G. K., Dodson J. M., Montgomery P. A., et al. p185HER2 Signal Transduction in Breast Cancer Cells. J. Biol. Chem. 1991; 266(22)14300–14305
   PubMed Web of Science ®Google Scholar
• Lewis G. D., Figari I., Fendly B., et al. Differential Responses of Human Tumor Cell Lines to Anti-p185HER2 Monoclonal Antibodies. Cancer Immunol. Immunother. 1993; 37: 255–263
   PubMed Web of Science ®Google Scholar
• Pietras R. J., Fendly B. M., Chazin V. R., et al. Antibody to HER-2/neu Receptor Blocks DNA Repair After Cisplatin in Human Breast and Ovarian Cancer Cells. Oncogene 1994; 9: 1829–1838
   PubMed Web of Science ®Google Scholar
• Shepard H. M., Lewis G. D., Sarup J. C., et al. Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic. J. Clin. Immunol. 1991; 11: 117–127
   PubMed Web of Science ®Google Scholar
• Witters L. M., Kumar R., Chinchilli V. M., et al. Enhanced Anti-proliferative Activity of the Combination of Tamoxifen Plus HER-2-neu Antibody. Breast Cancer Res. Treat. 1997; 42: 1–5
   PubMed Web of Science ®Google Scholar
• Ohnishi Y., Nakamura H., Yoshimura M., et al. Prolonged Survival of Mice with Human Gastric Cancer Treated with an Anti-c-ErbB-2 Monoclonal Antibody. Br. J. Cancer 1995; 71: 969–973
   PubMed Web of Science ®Google Scholar
• Sarup J. C., Johnson R. M., King K. L., et al. Characterization of an Anti p185HER2 Monoclonal Antibody That Stimulates Receptor Function and Inhibits Tumor Cell Growth. Growth Regul. 1991; 1: 72–82
   PubMedGoogle Scholar
• Flicker S. H., Schneider S. M., Offterdinger M., et al. Tyrosine Kinase Signaling Pathways Control the Expression of Retinoic Acid Receptor-alpha in SK-BR-3 Breast Cancer Cells. Cancer Lett. 1997; 115: 63–72
   PubMed Web of Science ®Google Scholar
• Kumar R., Shepard H. M., Mendelsohn J. Regulation of Phosphorylation of the c-erbB-2/HER2 Gene Product by a Monoclonal Antibody and Serum Growth Factor(s) in Human Mammary Carcinoma Cells. J. Mol. Cell. Biol. 1991; 11: 979–986
   Web of Science ®Google Scholar
• D'souza B., Taylor-Papadimitriou J. Overexpression of ERBB-2 in Human Mammary Epithelial Cells Signals Inhibition of Transcription of the E-cadherin Gene. Proc. Natl. Acad. Sci. USA 1994; 91: 7202–7206
   PubMed Web of Science ®Google Scholar
• Viloria Petit A. M., Rak J., Hung M. C., et al. Neutralizing Antibodies Against Epidermal Growth Factor and ErbB-2/neu Receptor Tyrosine Kinases Down-regulate Vascular Endothelial Growth Factor Production by Tumor Cell in Vitro and in Vivo: Angiogenic Implications for Signal Transduction Therapy of Solid Tumors. Am. J. Pathol. 1991; 151: 1523–1530
   Google Scholar
• Morrison S. L., Johnson M. J., Herzenberg L. A., et al. Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains. 1984; 81: 6851–6855
   Google Scholar
• Boulianne G. L., Hozumi N., Ulman M J. Production of Functional Chimaeric Mouse/Human Antibody. Nature 1984; 312: 643–646
   PubMed Web of Science ®Google Scholar
• Neuberger M. S., Williams G. T., Mitchell E., et al. A Hapten-Specific Chimaeric IgE Antibody with Human Physiological Effector Function. Nature 1985; 314: 268–270
   PubMed Web of Science ®Google Scholar
• Mountain A., Adair J. Engineering Antibodies for Therapy. Biotechnol. Genetic Engineering Rev. 1992; 10: 1–142
   PubMedGoogle Scholar
• Jones P. T., Dear P. H., Foote J., et al. Replacing the Complementarity-determining Regions in a Human Antibody with Those from a Mouse. Nature 1986; 321: 522–525
   PubMed Web of Science ®Google Scholar
• Riechmann L., Clark M., Waldmann H., et al. Reshaping Human Antibodies for Therapy. Nature 1988; 332: 323–327
   PubMed Web of Science ®Google Scholar
• Verhoeyen M., Milstein C., Winter G. Reshaping Human Antibodies: Grafting an Antilysozyme Activity. Science 1988; 239: 1534–1546
   PubMed Web of Science ®Google Scholar
• Carter P., Gorman C. D., Presta L., et al. Humanization of an anti-p185HER-2 Antibody for Human Cancer Therapy. Proc. Natl. Acad. Sci. USA 1992; 89: 4285–4289
   PubMed Web of Science ®Google Scholar
• Kelley R. F., O'Connell M. P., Carter P., et al. Antigen Binding Thermodynamics and Antiproliferative Effects of Chimeric and Humanized Anti-p185HER2 Antibody Fab Fragments. Biochemistry 1992; 31: 5434–5441
   PubMed Web of Science ®Google Scholar
• Eigenbrot C., Randal M., Presta L., et al. X-ray Structures of the Antigen-binding Domains from Three Variants of Humanized Anti-p185HER2 Antibody 4D5 and Comparison with Molecular Modeling. J. Mol. Biol. 1993; 229: 969–995
   PubMed Web of Science ®Google Scholar
• Kopreski M. S., Lipton A., Harvey H. A., et al. Growth Inhibition of Breast Cancer Cell Lines by Combinations of Anti-P185HER2 Monoclonal Antibody and Cytokines. Anticancer Res. 1996; 16: 433–436
   PubMed Web of Science ®Google Scholar
• Xing R., Wu F., Mason R. W. Control of Breast Tumor Cell Growth Using a Targeted Cysteine Protease Inhibitor. Cancer Res. 1998; 58: 904–909
   PubMed Web of Science ®Google Scholar
• Pietras R. J., Pegram M. D., Finn R. S., et al. Remission of Human Breast Cancer Xenografts on Therapy with Humanized Monoclonal Antibody to HER-2 Receptor and DNA-reactive Drugs. Oncogene 1998; 17: 2235–2249
   PubMed Web of Science ®Google Scholar
• Baselga J., Norton L., Albanell J., et al. Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin Against HER2/neu Overexpressing Human Breast Cancer Xenografts. Cancer Res. 1998; 58: 2825–2831
   PubMed Web of Science ®Google Scholar
• Baselga J., Tripathy D., Mendelsohn J., et al. Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER-2 Monoclonal Antibody in Patients with HER-2/neu Overexpressing Metastatic Breast Cancer. J. Clin. Oncol. 1996; 14: 737–744
   PubMed Web of Science ®Google Scholar
• Pegram M. D., Lipton A., Hayes D. F., et al. Phase II Study of Receptor-enhanced Chemosensitivity Using Recombinant Humanized Anti-p185HER2/neu Monoclonal Antibody Plus Cisplatin in Patients with HER2/neu-overexpressing Metastatic Breast Cancer Refractory to Chemotherapy Treatment. J. Clin. Oncol. 1998; 16: 2659–2671
   PubMed Web of Science ®Google Scholar
• Cobleigh M. A., Vogel C. L., Tripathy N. J., et al. Efficacy and Safety of Herceptin (humanized Anti-HER-2 Antibody) as a Single Agent in 222 Women with HER-2 Overexpression Who Relapsed Following Chemotherapy for Metastatic Breast Cancer [Abstract 376]. Proc. Am. Soc. Clin. Oncol. 1998; 16: 376
   Google Scholar
• Vogel C. L., Cobleigh M. A., Tripathy D., et al. Efficacy and Safety of Herceptin (Trastuzumab, Humanized Anti-HER-2 Antibody) as a Single Agent in First-Line Treatment of HER-2 Overexpressing Metastatic Breast Cancer (HER−2+/MBC) [Abstract 23]. 21st Annual San Antonio Breast Cancer Symposium. San Antonio, , TX 1998
   Google Scholar
• Arteaga C. L., Winnier A. R., Poirier M. C., et al. p185c-erbB-2 Signal Enhances Cisplatin-Induced Cytotoxicity in Human Breast Carcinoma Cells: Association Between an Oncogenic Receptor Tyrosine Kinase and Drug-Induced DNA Repair. Cancer Res. 1994; 54: 3758–3765
   PubMed Web of Science ®Google Scholar
• Slamon D., Leyland Jones B., Shak S., et al. Addition of Herceptin (Humanized Anti-HER-2 Antibody) to First Line Chemotherapy for HER-2 Overexpressing Metastatic Breast Cancer (HER−2+/MBC) Markedly Increases Anticancer Activity: A Randomized, Multinational Controlled Phase III Trial [Abstract 377]. Proc. Am. Soc. Clin. Oncol. 1998; 17: 377
   Google Scholar
• Norton L., Slamon D., Leyland-Jones B., Wolter J., Flaming T., Eirmann W., Baselga J., Mendelsohn J., Bajamonde A., Ash M., Shak S. Overall Survival Advantage to Simultaneous Chemotherapy Plus the Humanized Anti-HER2 Monoclonal Antibody Herceptin in HER2-overexpressiong Metastatic Breast Cancer [Abstract 483]. Proc. Am. Soc. Clin. Oncol. 1998; 18: 127
   Google Scholar
• Hudis C., Seidman A., Paton V., et al. Characterization of Cardiac Dysfunction in the Herceptin (Trastuzumab) Clinical Trials [Abstract 24]. 21st Annual San Antonio Breast Cancer Symposium. San Antonio, , TX 1998
   Google Scholar
• Ye D., Mendelsohn J., Fan Z. Augmentation of a Humanized Anti-HER2 mAb 4D5 Induced Growth Inhibition by a Human-Mouse Chimeric Anti-EGF Receptor mAb C225. Oncogene 1999; 18: 731–738
   PubMed Web of Science ®Google Scholar